Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 7/20 | 0.44 |
| ▸ | WHR1 | P49842 | 2/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.41 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.35 |
| ▸ | SPIN4 | Q56A73 | 1/20 | 0.35 |
| ▸ | SPIN3 | Q5JUX0 | 1/20 | 0.35 |
| ▸ | SPIN2B | Q9BPZ2 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | DNM2 | P50570 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679538 | 0.96 | KDM1A (0.43) | KDM1ARCOR1WHR1EHMT2SPIN1 | |
| SCHEMBL6673922 | 0.89 | DNM2 (0.37) | KDM1ARCOR1WHR1EHMT2DNM2 | |
| SCHEMBL2776640 | 0.82 | KDM1A (0.42) | KDM1ARCOR1WHR1EHMT2 | |
| SCHEMBL6833397 | 0.81 | CRHBP (0.43) | KDM1ARCOR1WHR1EHMT2 | |
| SCHEMBL2774178 | 0.80 | KCNH2 (0.40) | KDM1ARCOR1EHMT2DNM2 | |
| SCHEMBL2777536 | 0.79 | KCNH2 (0.40) | KDM1ARCOR1DNM2 | |
| SCHEMBL3388870 | 0.77 | PABPC1 (0.36) | KDM1ARCOR1WHR1EHMT2SPIN1 | |
| SCHEMBL3390138 | 0.77 | CA12 (0.35) | KDM1ARCOR1WHR1EHMT2SPIN1 | |
| SCHEMBL6676763 | 0.77 | CA1 (0.37) | — | |
| SCHEMBL2776366 | 0.77 | SCN9A (0.42) | KDM1ARCOR1EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | KDM1A 580/4885RCOR1 475/4885WHR1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.